Literature DB >> 33725725

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic.

Maria R Farcet1, Michael Karbiener1, Julia Schwaiger1, Reinhard Ilk2, Thomas R Kreil1.   

Abstract

Immunoglobulin lots (N = 176) released since March 2020 were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, with first positive results for September 2020 lots (mean, 1.7 IU/mL; 46% of lots positive). From there, values steadily increased, in correlation with the cumulative coronavirus disease 2019 (COVID-19) incidence, to reach a mean of 31.2 IU/mL and 93% of lots positive by January 2021. Extrapolating the correlation, immunoglobulins could reach an anti-SARS-CoV-2 potency of approximately 345 IU/mL by July 2021. At that stage, prophylactic immunoglobulin treatment for primary/secondary immunodeficiency could contain similar doses of anti-SARS-CoV-2 as convalescent plasma that is used for treatment of COVID-19.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; SARS-CoV-2 antibody potency; immunoglobulin; intravenous immune globulin; neutralizing antibodies; plasma; primary immunodeficiency; prophylaxis; secondary immunodeficiency

Mesh：

Substances：

Year:  2022        PMID： 33725725      PMCID： PMC7989343          DOI： 10.1093/infdis/jiab142

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   7.759


  7 in total

1.  An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Authors:  Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel
Journal:  N Engl J Med       Date:  2020-07-14       Impact factor: 91.245

2.  No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.

Authors:  Julia Schwaiger; Michael Karbiener; Claudia Aberham; Maria R Farcet; Thomas R Kreil
Journal:  J Infect Dis       Date:  2020-11-13       Impact factor: 5.226

3.  Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.

Authors:  Michael J Joyner; Rickey E Carter; Jonathon W Senefeld; Stephen A Klassen; John R Mills; Patrick W Johnson; Elitza S Theel; Chad C Wiggins; Katelyn A Bruno; Allan M Klompas; Elizabeth R Lesser; Katie L Kunze; Matthew A Sexton; Juan C Diaz Soto; Sarah E Baker; John R A Shepherd; Noud van Helmond; Nicole C Verdun; Peter Marks; Camille M van Buskirk; Jeffrey L Winters; James R Stubbs; Robert F Rea; David O Hodge; Vitaly Herasevich; Emily R Whelan; Andrew J Clayburn; Kathryn F Larson; Juan G Ripoll; Kylie J Andersen; Matthew R Buras; Matthew N P Vogt; Joshua J Dennis; Riley J Regimbal; Philippe R Bauer; Janis E Blair; Nigel S Paneth; DeLisa Fairweather; R Scott Wright; Arturo Casadevall
Journal:  N Engl J Med       Date:  2021-01-13       Impact factor: 91.245

4.  Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.

Authors:  Romina Libster; Gonzalo Pérez Marc; Diego Wappner; Silvina Coviello; Alejandra Bianchi; Virginia Braem; Ignacio Esteban; Mauricio T Caballero; Cristian Wood; Mabel Berrueta; Aníbal Rondan; Gabriela Lescano; Pablo Cruz; Yvonne Ritou; Valeria Fernández Viña; Damián Álvarez Paggi; Sebastián Esperante; Adrián Ferreti; Gastón Ofman; Álvaro Ciganda; Rocío Rodriguez; Jorge Lantos; Ricardo Valentini; Nicolás Itcovici; Alejandra Hintze; M Laura Oyarvide; Candela Etchegaray; Alejandra Neira; Ivonne Name; Julieta Alfonso; Rocío López Castelo; Gisela Caruso; Sofía Rapelius; Fernando Alvez; Federico Etchenique; Federico Dimase; Darío Alvarez; Sofía S Aranda; Clara Sánchez Yanotti; Julián De Luca; Sofía Jares Baglivo; Sofía Laudanno; Florencia Nowogrodzki; Ramiro Larrea; María Silveyra; Gabriel Leberzstein; Alejandra Debonis; Juan Molinos; Miguel González; Eduardo Perez; Nicolás Kreplak; Susana Pastor Argüello; Luz Gibbons; Fernando Althabe; Eduardo Bergel; Fernando P Polack
Journal:  N Engl J Med       Date:  2021-01-06       Impact factor: 91.245

5.  A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.

Authors:  Ventura A Simonovich; Leandro D Burgos Pratx; Paula Scibona; María V Beruto; Marcelo G Vallone; Carolina Vázquez; Nadia Savoy; Diego H Giunta; Lucía G Pérez; Marisa Del L Sánchez; Andrea Vanesa Gamarnik; Diego S Ojeda; Diego M Santoro; Pablo J Camino; Sebastian Antelo; Karina Rainero; Gabriela P Vidiella; Erica A Miyazaki; Wanda Cornistein; Omar A Trabadelo; Fernando M Ross; Mariano Spotti; Gabriel Funtowicz; Walter E Scordo; Marcelo H Losso; Inés Ferniot; Pablo E Pardo; Eulalia Rodriguez; Pablo Rucci; Julieta Pasquali; Nora A Fuentes; Mariano Esperatti; Gerardo A Speroni; Esteban C Nannini; Alejandra Matteaccio; Hernán G Michelangelo; Dean Follmann; H Clifford Lane; Waldo H Belloso
Journal:  N Engl J Med       Date:  2020-11-24       Impact factor: 91.245

6.  Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.

Authors:  Samaneh Delavari; Hassan Abolhassani; Farhad Abolnezhadian; Fateme Babaha; Sara Iranparast; Hamid Ahanchian; Nasrin Moazzen; Mohammad Nabavi; Saba Arshi; Morteza Fallahpour; Mohammad Hassan Bemanian; Sima Shokri; Tooba Momen; Mahnaz Sadeghi-Shabestari; Rasol Molatefi; Afshin Shirkani; Ahmad Vosughimotlagh; Molood Safarirad; Meisam Sharifzadeh; Salar Pashangzadeh; Fereshte Salami; Paniz Shirmast; Arezou Rezaei; Tannaz Moeini Shad; Minoo Mohraz; Nima Rezaei; Lennart Hammarström; Reza Yazdani; Asghar Aghamohamamdi
Journal:  J Clin Immunol       Date:  2020-12-01       Impact factor: 8.317

7.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

Authors:  Edward E Walsh; Robert W Frenck; Ann R Falsey; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; Kathleen Neuzil; Mark J Mulligan; Ruth Bailey; Kena A Swanson; Ping Li; Kenneth Koury; Warren Kalina; David Cooper; Camila Fontes-Garfias; Pei-Yong Shi; Özlem Türeci; Kristin R Tompkins; Kirsten E Lyke; Vanessa Raabe; Philip R Dormitzer; Kathrin U Jansen; Uğur Şahin; William C Gruber
Journal:  N Engl J Med       Date:  2020-10-14       Impact factor: 91.245
  7 in total
  13 in total

1.  SARS-CoV-2 symptomatic reinfection among patients with primary antibody deficiency.

Authors:  Nufar Marcus; Liat Ashkenazi-Hoffnung; Adi Ovadia; Ilan Dalal; Siril Yoffe; Nesia Kropach; Neta Zuckerman; Oded Scheuerman
Journal:  J Allergy Clin Immunol Pract       Date:  2022-05-19

Review 2. 

Authors:  Eva Untersmayr; Elisabeth Förster-Waldl; Michael Bonelli; Kaan Boztug; Patrick M Brunner; Thomas Eiwegger; Kathrin Eller; Lisa Göschl; Katharina Grabmeier-Pfistershammer; Wolfram Hötzenecker; Galateja Jordakieva; Alexander R Moschen; Birgit Pfaller; Winfried Pickl; Walter Reinisch; Ursula Wiedermann; Ludger Klimek; Karl-Christian Bergmann; Randolf Brehler; Natalija Novak; Hans F Merk; Uta Rabe; Wolfgang W Schlenter; Johannes Ring; Wolfgang Wehrmann; Norbert K Mülleneisen; Holger Wrede; Thomas Fuchs; Erika Jensen-Jarolim
Journal:  Allergo J       Date:  2021-08-13

3.  Seroconversion Following COVID-19 Vaccination in Immune Deficient Patients.

Authors:  Jacqueline Squire; Dr Avni Joshi
Journal:  Ann Allergy Asthma Immunol       Date:  2021-05-19       Impact factor: 6.347

4.  Detection of antibodies against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins produced from plasma collected in Italy during the pandemic.

Authors:  Giulio Pisani; Karen Cristiano; Matteo Simeoni; Antonio Martina; Ilaria Pati; Alberto Carocci; Andrea Gaggioli; Francesco Marino; Daniela Adriani; Simonetta Pupella; Fabio Candura; Vincenzo De Angelis
Journal:  Blood Transfus       Date:  2021-05-27       Impact factor: 5.752

5.  Vaccine-induced immune thrombotic thrombocytopenia: Consider IVIG batch in the treatment.

Authors:  Anupama Karnam; Sébastien Lacroix-Desmazes; Srini V Kaveri; Jagadeesh Bayry
Journal:  J Thromb Haemost       Date:  2021-07       Impact factor: 5.824

Review 6.  Passive Immunity Should and Will Work for COVID-19 for Some Patients.

Authors:  Nevio Cimolai
Journal:  Clin Hematol Int       Date:  2021-04-16

7.  Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines.

Authors:  Michael Karbiener; Maria R Farcet; Andreas Zollner; Taisei Masuda; Mitsuhiro Mori; Alexander R Moschen; Thomas R Kreil
Journal:  NPJ Vaccines       Date:  2022-02-18       Impact factor: 7.344

8.  SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.

Authors:  Sophie Steiner; Tatjana Schwarz; Victor M Corman; Laura Gebert; Malte C Kleinschmidt; Alexandra Wald; Sven Gläser; Jan M Kruse; Daniel Zickler; Alexander Peric; Christian Meisel; Tim Meyer; Olga L Staudacher; Kirsten Wittke; Claudia Kedor; Sandra Bauer; Nabeel Al Besher; Ulrich Kalus; Axel Pruß; Christian Drosten; Hans-Dieter Volk; Carmen Scheibenbogen; Leif G Hanitsch
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

9.  SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.

Authors:  Andreas Volk; Caroline Covini-Souris; Jürgen Römisch; Torben Schmidt; Denis Kuehnel; Christian De Mey
Journal:  BioDrugs       Date:  2021-11-29       Impact factor: 5.807

10.  Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients.

Authors:  Friederike Bachmann; Klemens Budde; Norbert Suttorp; Tilman Lingscheid; Miriam Songa Stegemann; Bilgin Osmanodja; Eva Schrezenmeier; Wiebke Duettmann; Ulrike Weber; Marcel Naik; Lukas Johannes Lehner; Andreas Kahl; Michael Duerr; Kai-Uwe Eckardt; Johannes Waiser; Mira Choi; Fabian Halleck
Journal:  Transpl Int       Date:  2022-03-31       Impact factor: 3.782
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.